Strekin AG
Differentiated medicines in the area of stress related inflammatory processes
Strekin AG is a privately held, clinical-stage biopharmaceutical company dedicated to developing novel pharmaceutical and biotechnology products. Strekin focuses on discovering the untapped therapeutic potential in existing molecules to transform the lives of patients with diseases of cell stress-related inflammatory pathways.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
10.09.2019
Strekin closes CHF2.8 million Series A round (startupticker.ch)
06.06.2017
Strekin AG Secures CHF 10 Million Financing (startupticker.ch)
06.06.2017
Strekin AG Secures CHF 10 Million Financing (startupticker.ch)
02.05.2017
Strekin’s development candidate obtains EU orphan drug designation (startupticker.ch)
02.05.2017
Strekin?s development candidate obtains EU orphan drug designation (startupticker.ch)
No milestones
No Jobs
No videos and documents
No Awards
Strekin AG
Differentiated medicines in the area of stress related inflammatory processes
Website:
www.strekin.com
Headquarter:
Basel
Foundation Date:
August 2014
Technology:
- Biotech